Similar articles

• Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study.

  Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Hudson M, et al. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):602-9. doi: 10.1016/j.ejheart.2007.02.001. Epub 2007 Mar 26. Eur J Heart Fail. 2007. PMID: 17383932
• ACEI and ARB may also benefit CHF through immune system modulation (down-regulation of immune system).

  Fett JD. Fett JD. Int J Cardiol. 2005 Aug 3;103(1):107. doi: 10.1016/j.ijcard.2004.06.019. Int J Cardiol. 2005. PMID: 16061132 No abstract available.
• No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.

  Han SW, Won YW, Yi JH, Kim HJ. Han SW, et al. Nephrol Dial Transplant. 2007 Apr;22(4):1150-5. doi: 10.1093/ndt/gfl752. Epub 2007 Jan 25. Nephrol Dial Transplant. 2007. PMID: 17255126 Clinical Trial.
• Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

  Weir MR. Weir MR. Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
• Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.

  Vijan SG. Vijan SG. J Indian Med Assoc. 2009 Mar;107(3):178-82. J Indian Med Assoc. 2009. PMID: 19810392 Review.